Management & Regulatory

Will Trump or Harris Shape the Future of US Drug Pricing Reforms?
Management & Regulatory Will Trump or Harris Shape the Future of US Drug Pricing Reforms?

As the U.S. presidential election looms, the conversation around pharmaceutical policies intensifies, with Vice President Kamala Harris and former President Donald Trump proposing divergent paths. Harris and Trump represent fundamentally different approaches to drug pricing reforms, reflecting

Innovations Driving Efficiency and Sustainability in Biopharma Manufacturing
Management & Regulatory Innovations Driving Efficiency and Sustainability in Biopharma Manufacturing

The biopharmaceutical industry is undergoing a significant transformation, driven by the need for speed, safety, and cost-efficiency in therapeutic production. The advent of new modalities like cell and gene therapies has added layers of complexity to the already intricate production pipelines. As

Is Xeris Biopharma Holdings Inc a Promising Investment Opportunity?
Management & Regulatory Is Xeris Biopharma Holdings Inc a Promising Investment Opportunity?

The biotech industry is bustling with innovation and potential, and Xeris Biopharma Holdings Inc (NASDAQ: XERS) is making waves. This article aims to delve deep into the nuts and bolts of Xeris Biopharma’s recent market activities, financial health, insider trading, analysts' ratings, v

Why Are Major Biopharma Companies Cutting Jobs in 2024?
Management & Regulatory Why Are Major Biopharma Companies Cutting Jobs in 2024?

The biopharma sector is facing a significant wave of layoffs in 2024, affecting thousands of employees across various companies. This trend is shaped by numerous internal and external factors, including corporate restructuring, market adaptations, strategic divestments, and cost-saving measures.

Advancements in Automation Revolutionize Biopharmaceutical Manufacturing
Management & Regulatory Advancements in Automation Revolutionize Biopharmaceutical Manufacturing

The biopharmaceutical manufacturing sector stands at the brink of a revolution, driven by the relentless pursuit of speed, safety, and scalability. The emergence of new therapeutic modalities, coupled with the increasing demand for rapid and cost-effective production solutions, has necessitated a

Catalent Sells N.J. Facility to Ardena Amid Expansion and Acquisition Plans
Management & Regulatory Catalent Sells N.J. Facility to Ardena Amid Expansion and Acquisition Plans

Catalent, a prominent contract development and manufacturing organization (CDMO), has announced the divestment of its Somerset, New Jersey, oral solids development and small-scale manufacturing facility to Ardena, a Belgian CDMO. This transaction marks Ardena's entry into the U.S. market and

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later